• Securing first-mover position in new segment of men's health market
• Developing seaweed extract-based formulations to support male vitality, stamina, and wellbeing
• Initial focus on natural OTC supplement, with potential for evidence-based clinical development

BPH Global Ltd (ASX:BP8) is expanding its research and development initiatives to include seaweed-based natural formulations intended to support male vitality, performance, and overall wellbeing. To the Company's knowledge, there are currently no approved or commercially marketed seaweed-based products specifically targeting erectile dysfunction, providing BPH Global with a first-mover position in leveraging marine bioactives for men's health and performance enhancement. The formulations will combine proprietary seaweed extracts with botanical and marine-derived ingredients, drawing upon both traditional wellness practices and emerging marine biochemistry research to deliver safe, effective, and naturally derived solutions. The Company's initial approach will be to produce a Natural Over-the-Counter (OTC) supplement product based on this formulation. Should early research and testing produce supportive results, the Company may also pursue the more rigorous, evidence-based development pathway, including clinical validation. BPH Global continues to pursue a two-tiered R&D strategy, combining in-house research led by Gaia Mariculture Pte Ltd with outsourced specialist collaborations to optimise innovation, efficiency, and timelines.

BPH Global will continue to evaluate and develop opportunities within the marine bioresource, nutraceutical, and functional wellbeing sectors, leveraging its biotechnology capabilities and strategic partnerships.